The influence of exogenous magnesium chloride on the apparent INR determined with human, rabbit, and bovine thromboplastin reagents

Summary

Magnesium ions can shorten the tissue factor-induced coagulation time. Some blood collection systems with sodium citrate are contaminated with variable amounts of magnesium and influence the results of the prothrombin time (PT) test. The aim of the study was to determine the dose-response relationship between exogenous magnesium chloride added to blood and the PT and the international normalized ratio (INR). Blood specimens from twenty patients on oral anticoagulant therapy were investigated. Four different types of thromboplastin reagents were used: recombinant human, human placenta, rabbit brain, and bovine brain combined with adsorbed bovine plasma. With all four reagents, exogenous magnesium induced a reduction of the apparent INR. Bovine thromboplastin was not as responsive to magnesium as the human and rabbit reagents. The magnitude of the INR deviation induced by 0.1 mmol/l magnesium in the blood was smaller than 10% in all patient samples. At 0.5 mmol/l magnesium in the blood, 10-35% of the patient samples had INR deviations greater than 10%, depending on the thromboplastin reagent used.

Keywords

Prothrombin time - international normalized ratio - blood collection tube - magnesium - preanalytical conditions

• References

• 1 Van den Besselaar AMHP, Van Dam W, Sturk A, Bertina RM. Prothrombin time ratio is reduced by magnesium contamination in evacuated blood collection tubes. Thromb Haemost 2001; 85: 647-50.
• 2 Van den Besselaar AMHP. Magnesium and manganese ions accelerate tissue factor-induced coagulation independently of factor IX. Blood Coagul Fibrinolysis 2002; 13: 1-5.
• 3 Poller L, Barrowcliffe TW, Van den Besselaar AMHP, Jespersen J, Tripodi A, Houghton D. Minimum lyophilized plasma requirement for ISI calibration. Am J Clin Pathol 1998; 109: 196-204.
• 4 Turpie AGG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988; I: 1242-5.
• 5 Saour JN, Sieck JO, Mamo LAR, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428-32.
• 6 Tripodi A, Chantarangkul V, Negri B, Clerici M, Mannucci PM. International collaborative study for the calibration of a proposed reference preparation for thromboplastin, human recombinant, plain. Thromb Haemost 1998; 79: 439-43.